EIP logo

Copyright © 2007-2026 European Immunogenicity Platform

Location photo (landscape)

17th Open Scientific EIP Symposium on Immunogenicity of Biopharmaceuticals

16th — 19th March 2026

Altis Grand Hotel, Lisbon, Portugal

Program

Download the program as a PDF
 

Monday, March 16th 2026

09:00 Welcome and Introduction by the EIP Chairman
Daniel Kramer, Sanofi
09:15 Keynote Presentation: Innate Immunity
Bruno Lemaître, EPFL
10:15 coffee Coffee Break
Trainings — Parallel Sessions
10:45 Beginner Immunogenicity Beginner Training: Mechanisms of Immunogenicity; Overview of Non-Clinical Risk Assessment Tools
Chloé Ackaert, IQVIA
Sofie Pattyn, IQVIA
Noel Smith, Lonza
Sophie Tourdot, Pfizer
10:45 Advanced Immunogenicity Advanced Training: Interactions With Health Agencies: Real Life Examples
Daniel Kramer, Sanofi
Lydia Michaut, Novartis
Sebastian Spindeldreher, Integrated Biologix
12:00 cutlery 77 Lunch Break
13:00 Session 1 Bring Your Own Problems — Break Out Session: Immunogenicity Assays, Assay Strategy, Immunogenicity Risk Assessment
Daniel Kramer, Sanofi
Arno Kromminga, BioNTech
Lydia Michaut, Novartis
Denise Sickert, Roche
Veerle Snoeck, UCB
Christopher Tiedje, BioAgilytix
Main Program
Session 1: Immunogenicity of New Modalities
Chair: Lydia Michaut, Novartis
14:45 Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASOs, siRNAs, and non-vaccine mRNA/LNPs
Joanna Grudzinska-Goebel, Bayer
15:15 Imlifidase Treatment for Overcoming Pre-Formed Immunity
Hitto Kaufmann, Hansa Biopharma
15:45 Minimizing immunogenicity testing for development of oligonucleotide therapeutics: A risk-based strategy
An Zhao, Regeneron Pharmaceuticals
16:15 coffee Coffee Break
16:45 Transient blockade of the CD28/B7 costimulatory pathway with abatacept inhibits immune responses to AAV vector and transgene product
Rebecca Xicluna, Roche
17:15 Advancing Immunogenicity Testing: Overcoming Drug Tolerance in a Neutralising Antibody Assay for a mRNA-Based Oncology Therapeutic
Juliane Ober-Blöbaum, Moderna
17:45 Immunogenicity Risk Assessment and Mitigation Strategy for AAV Gene Therapy
Hélène Haegel, Roche
18:15 End of Day 1
 

Tuesday, March 17th 2026

Session 2: Regulatory
Chair: Daniel Kramer, Sanofi
9:00 Immunogenicity, Where we Have Been and Where we are Going
Susan Kirshner, Consultant (former FDA)
9:30 The Slings and Arrows of Outrageous Product Quality Fortune- Current Immunogenicity Risk Perspectives from CDER’s Office of Pharmaceutical Quality
Joao Pedras-Vasconcelos, FDA
10:00 Harmonizing Adalimumab Anti-Drug Antibody Assays through WHO International Standards
Meenu Wadhwa, Medicines and Healthcare Products Regulatory Agency
10:30 coffee Coffee Break
11:00 Rethinking Immunogenicity Testing Paradigm: Leveraging Risk Assessment Outputs to Support Clinical Development
Vibha Jawa, EpiVax & Lauren Stevenson, Immunologix
Session 3: Immunogenicity of Therapeutic Peptides
Chair: Arno Kromminga, BioNTech
11:30 Immunogenicity Risk in Peptide Therapeutics: Navigating Complexity, Prediction tools, and Bioanalytical Strategies
Montserrat Puig, Merck Sharp & Dohme
12:00 Aligning Regulatory Expectations on Immunogenicity to Support Peptide Drug Product Approvals
Laura Salazar-Fontana, Immunogenicity Integrated
12:30 cutlery 77 Lunch Break
Session 4: Immunogenicity Assays
Chair: Christopher Tiedje, BioAgilytix
14:00 EIP Immunogenicity Assays and EIP Immunogenicity Risk Assessment Working Group Update
Linlin Luo, Merck Sharp & Dohme on behalf of EIP Assay Working Group
Joanna Grudzinska-Goebel, Bayer on behalf of the EIP Immunogenicity Risk Assessment (IRA) Working Group
14:30 Overcoming Unexpected Interference in a Highly Drug-Tolerant and Ultrasensitive ADA-SPEAD Assay
Florian Anlauff, BioAgilytix
15:00 PABAD in Practice: Achieving High Drug Tolerance in NAb Assays
Lysie Champion, Celerion
15:30 When Generic Assays Succeed (and Fail): Case Studies and a Fit-for-Purpose Strategy for Non-Clinical ADA Support
Noor Bodrul, Roche
16:00 coffee Coffee Break
16:30 The Immunogenicity Nexus: Investigating the Predictive Relationship Between Early-Onset ADA Kinetics in NHP and Human Immune Responses
Yana Van Den Bossche, Sanofi
17:00 Positive Controls in Immunogenicity Assays: Case Studies and Best Practices
Esther Biemans, Ardena
17:30 A Drug and Target-Tolerant Hybrid LBA-LC-MS Method for (Semi-)Quantification of ADA Isotopes, Using a Single-Tier Approach
Hendrik Folkerts, ICON Bioanalytical Laboratory
18:00 End of Day 2
 

Wednesday, March 18th 2026

Session 5: Biosimilars
Chair: Denise Sickert
09:00 EIP Biosimilar Working Group Update
Martin Ullmann, Fresenius Kabi on behalf of EIP
09:15 Establishing In-Vitro Assays for Non-Clinical Immunogenicity Assessment of Bio-similars
Marc Rosenbaum, Hexal AG
09:45 Biosimilar Medicines: The Story of European Pioneering Success in Advancing Patient Access to Lifesaving Biologic Treatment
Karsten Roth, Polpharma Biologics
10:15 A Comparative Analysis of Antidrug Antibody Incidences of EU and US Approved Biosimilars and their Reference Products Reported in Single-Dose PK Studies in Healthy Volunteers and Multidose Studies in Patients
Hans Ebbers, Alvotech
10:45 Coffee Break
Session 6: Prediction of Immunogenicity
Chair: Sofie Pattyn
11:15 EIP NCIRA Working Group Update
Sebastian Spindeldreher, Integrated Biologix
11:30 Immunogenicity Risk Assessment: Enabling Quality by Design in Therapeutic Protein Discovery and Development
Tim Hickling, Quasor
Sophie Tourdot, Pfizer
12:00 How to translate pre-clinical in silico immunogenicity profiling results to clinical immunogenicity rates?
Michael Gutknecht, Novartis
12:30 cutlery 77 Lunch Break
12:30 canvas Poster Exhibition
13:30 Unmasking Hidden Epitopes: Bridging In Silico Prediction and MAPPs Detection in Immunogenicity Assessment
Andreas Hollenstein, Roche
14:00 Advancing Preclinical Immunogenicity Prediction: Machine Learning on Clinical Data and Pathogen Cross-Reactivity Integration
Olga Obrezanova, Astra Zeneca
14:30 An Innovative Reductionist Antigen Presenting System to Rapidly Screen Protein Immunogenicity in Human Lysosomes
Sergio Gabriele Colangelo, RBM S.p.A. (an affiliate of Merck KGaA)
Short Talk (10 minutes presentation; 5 minutes Q&A)
15:00 Improving TCR-pMHC Structure Prediction with TCR-Specific Spatial Restraint Features
Joakim Nøddeskov, Technical University of Denmark
15:15 coffee Coffee Break
Session 7: Clinical Relevance of Immunogenicity
Chair: Noel Smith, Lonza
15:45 Assessment of Long-term Immunogenicity of Lonapegsomatropin in Children With Growth Hormone Deficiency
Per Holse Mygind, Ascendis
Short Talk (10 minutes presentation; 5 minutes Q&A)
16:15 Immunogenicity Assessment in Acromegaly Patients Treated with Ready-to-Use, Sustained-Release, Octreotide Subcutaneous Depot
K. Järås, Camurus
16:30 Immunogenicity Publication Bias and Its Consequences for Predictive Models: A Call for Transparent Reporting
Sophie Tascedda, RC2NB
16:45 Move to lobby to take the bus
17:15 toast Session 8: Social Event
Departure
Chair: Barbara Vercruyssen
 

Thursday, March 19th 2026

Workshop – Parallel Sessions
09:00 Deep Dive 1 Recent Publication “Immunogenicity Risk Assessment for Tailored Mitigation and Monitoring of Biotherapeutics and Biosimilars”
Veerle Snoeck, UCB & Joanna Grudzinska-Goebel, Bayer on behalf of the EIP Immunogenicity Risk Assessment (IRA) Working Group
Deep Dive 2 Three Recent Publications of the NCIRA Working Group (EIP Recommendations for Dendritic Cell Maturation Assays, MAPPs and T-Cell Assays)
Sebastian Spindeldreher, Integrated Biologix on behalf of the EIP NCIRA Working Group
10:30 coffee Coffee Break
11:00 Deep Dive 1 In Depth Discussion
EIP Team
Deep Dive 2 In Depth Discussion
EIP Team
12:30 Summary and Outlook of the EIP Chairman
Daniel Kramer, Sanofi
12:45 End of the conference
Back to top